Välkommen till Via TT - det enkla pressverktyget

Pressvisning 18 december 13.00: Uplands konstförening har utsett Christopher Long till årets konstnärsprofil 2024. Uppsala konstmuseum visar hans utställning Between Apology Note And Love Poem.

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as pot

Ständigt sökande är den hittills största utställningen om Tyra Kleen. Ateljéstipendiaten Johan Ibrahim Adam frågar om inte World Wide Web är dagens heliga skrift i utställningen OMG. Dessutom är konsertprogrammet fyllt med spännande artister och populära Master class fortsätter.

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s Breakthrough Therapy Designation process aims to expedite the development of investigational medicines intended to treat severe conditions and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints.

Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons Grünenthal has expertise in developing human induced pluripotent stem cells towards sensory neurones and will support the lab of Dr Raouf with a total consideration of more than £350.000.

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 mil

Aachen, Germany – 7 July 2022

“BMW Esports Boost” brings together an international who's who of the esports world. The premiere of this globally unique format live from BMW Welt is on June 28, 2021. BMW is in partnership with Seven.One Sports. Gain fresh inspiration and exclusive insights from top industry experts such as Jens Hilgers, Ralf Reichert, Christopher Hana, Brandon Snow and Tobias Knoke. Exciting panel discussions and best practices are aimed at anyone who wants to invest in this market and help shape the future of esports. Tickets are available now at bmwesportsboost.com. Munich. Esports has long since developed from a niche sport into a global trend and an important economic factor. Through its commitment to esports, BMW is one of the driving forces in this fast-growing segment and wants to set new standards in storytelling and innovation. As the sports arm of the Seven.One Entertainment Group, Seven.One Sports has been actively promoting the broadcasting and reporting of all aspects of esports in Germ

Researchers at Karolinska Institutet in Sweden have investigated the long-term effect of hormonal therapy in women with the most common types of hormone-sensitive breast cancer. The results, presented in the journal JAMA Oncology, show that the treatment has a protective effect against distant metastatic cancer for both so-called Luminal A and Luminal B breast cancer subtypes, and a long-term effect for women diagnosed with Luminal A cancer.

Forskare vid Karolinska Institutet har undersökt den långsiktiga effekten av hormonbehandling hos kvinnor med de vanligaste typerna av hormonkänslig bröstcancer. Resultaten, som presenteras i tidskriften JAMA Oncology, visar att behandlingen har en skyddande effekt mot spridd cancer vid både så kallad Luminal A och Luminal B bröstcancersubtyp.

On August 23, the fourth Ingmar Bergman International Theatre Festival opens at the Royal Dramatic Theatre (Dramaten), offering eleven days of guest performances from countries that include Iran, Germany, the Netherlands, Norway, Austria, Brazil, France and Belgium. Six new Dramaten productions will premiere during the festival, a screening of Jane Magnusson's forthcoming film, Ingmar Bergman: A Year, a Life. When the festival ends on September 2, more than 200 visiting actors, directors and theatre technicians will have convened on the national stage in more than 50 productions, discussions, workshops and film screenings.

[PRESS RELEASE 2018-01-19] Researchers at Karolinska Institutet in Sweden have discovered that the risk of death from breast cancer is twice as high for patients with high heterogeneity of the oestrogen receptor within the same tumour as compared to patients with low heterogeneity. The study, which is published in The Journal of the National Cancer Institute, also shows that the higher risk of death over a span of 25 years is independent of other known tumour markers and also holds true for Luminal A breast cancer, a subtype with a generally good prognosis.

Forskare vid Karolinska Institutet har upptäckt att risken att dö av bröstcancer är dubbelt så stor för patienter med hög heterogenitet av östrogenreceptorn inom en och samma tumör jämfört med patienter med låg heterogenitet. Studien, som publiceras i Journal of the National Cancer Institute, visar också att den ökade risken att dö på 25 års sikt är oberoende av andra kända tumörmarkörer och gäller även vid så kallad Luminal A bröstcancersubtyp med generellt god prognos.

A study from Karolinska Institutet in Sweden has shown that neurons in our brain 'mirror' the space near others, just as if this was the space near ourselves. The study, published in the scientific journal Current Biology, sheds new light on a question that has long preoccupied psychologists and neuroscientists regarding the way in which the brain represents other people and the events that happens to those people.